1. INTRODUCTION
===============

With advancing understanding of oncogenesis and apoptosis comes an appreciation of the role cell-cycle regulation plays in malignant transformation. Modulation of the cell cycle also contributes to chemotherapy resistance. The cyclin-dependent kinases ([cdk]{.smallcaps}s), the essential engines of the cell cycle, are therefore rational therapeutic targets. Over the last several years, a new class of anticancer therapy has been developed and extensively tested: inhibitors of [cdk]{.smallcaps}s.

These drugs have been tested as single agents with modest results. However, in combination with traditional cytotoxic chemotherapy, they have the potential to overcome drug resistance and to improve cytotoxic efficacy.

2. THE CELL CYCLE AND ITS REGULATION
====================================

The cell cycle governs the transition from quiescence (G0) to proliferation while ensuring the fidelity of the genetic transcript. The phases associated with [dna]{.smallcaps} synthesis (S phase) and mitosis (M phase) are separated by the gaps G1 and G2. The [cdk]{.smallcaps}s join with regulatory proteins called cyclins to drive the cell through the cycle.

Inhibitory proteins \[[cdk]{.smallcaps} inhibitors ([cdki]{.smallcaps}s)\] block specific interactions. The Ink4 (inhibitor of [cdk]{.smallcaps}4) class of [cdki]{.smallcaps}s (p16^Ink4a^, p15^Ink4b^, p18^Ink4c^, and p19^Ink4^) bind and inhibit cyclin D--associated kinases ([cdk]{.smallcaps}2, -4, and -6), and the kinase inhibitor protein (Kip) group of [cdki]{.smallcaps}s (p21^Waf1^, p27^Kip1^, and p57^Kip2^) block the cyclin E/[cdk]{.smallcaps}2 and cyclin A/[cdk]{.smallcaps}2 complexes [@b1-co16-2-36].

The pattern of cyclin expression defines the cell's progression through the cycle [@b2-co16-2-36],[@b3-co16-2-36]. At least 9 [cdk]{.smallcaps}s ([cdk]{.smallcaps}1--[cdk]{.smallcaps}9) and many cyclins (cyclin A--cyclin T) are known. The [cdk]{.smallcaps}/cyclin complexes are activated by specific phosphorylation of the [cdk]{.smallcaps} by [cdk]{.smallcaps}7/cyclin H, also called [cdk]{.smallcaps}-activating kinase [@b4-co16-2-36]. Specific complexes regulate each step of the cycle. Cyclins D1--D3/[cdk]{.smallcaps}2, -4, and -6 drive progression through G1; cyclin E/[cdk]{.smallcaps}2 controls entry into S phase; cyclin A/[cdk]{.smallcaps}2 controls S-phase progression; cyclin A/ [cdk]{.smallcaps}1 (also known as [cdc]{.smallcaps}2) controls G2; and [cdk]{.smallcaps}1/ cyclin B facilitates mitosis.

Entry into the cell cycle (G1) is governed by the restriction point, beyond which progression through the cycle is independent of stimuli such as mitogens [@b5-co16-2-36]. Mitogens signal through the Ras/Raf/ [mapk]{.smallcaps} pathway leading to cyclin D production. The retinoblastoma tumour suppressor gene product (Rb) governs the G1/S transition. In its active state, Rb is hypophosphorylated and inhibits the transcription factors E2F--DP (E2F-1, -2, and -3). Rb is in turn phosphorylated by cyclin D/[cdk]{.smallcaps}4/6 and cyclin E/[cdk]{.smallcaps}2, modulating its activity [@b6-co16-2-36]. When partially phosphorylated, Rb remains bound to E2F-DP, but the transcription factor can still transcribe some genes such as cyclin E. Cyclin E then binds to [cdk]{.smallcaps}2, and the complex hyperphosphorylates Rb, releasing the E2F--DP complex and fully activating the E2F transcription factors. S-Phase proteins are then transcribed [@b7-co16-2-36].

Early in S phase, cyclins D and E are degraded [@b8-co16-2-36]. Cyclin A/[cdk]{.smallcaps}2 governs S-phase progression and the production of proteins involved in [dna]{.smallcaps} synthesis [@b9-co16-2-36],[@b10-co16-2-36]. Cyclin A/[cdk]{.smallcaps}2 also inactivates E2F [@b11-co16-2-36]--[@b14-co16-2-36].

In late S phase and throughout G2, levels of cyclins A and B rise. Cyclin B/[cdc]{.smallcaps}2 ([cdk]{.smallcaps}1) regulates the S-phase checkpoint. This replication checkpoint monitors progression through S phase and moderates [dna]{.smallcaps} synthesis [@b15-co16-2-36],[@b16-co16-2-36]. It is regulated by the [atm]{.smallcaps} (ataxia telangiectasia mutated) and [atr]{.smallcaps} ([atm]{.smallcaps} and Rad3-related) kinases and Chk1 and Chk2, which prevent cell-cycle progression in the event of [dna]{.smallcaps} damage [@b17-co16-2-36],[@b18-co16-2-36]. These pathways permit a cell to enter mitosis only after successful completion of S phase.

Mitosis is regulated by the anaphase-promoting complex/cyclosome and by degradation of cyclin B [@b10-co16-2-36]. The assembly of a bipolar spindle by the centrosome is monitored by a checkpoint that senses microtubule defects or aberrant kinetochore attachment [@b19-co16-2-36]--[@b21-co16-2-36]. Centrosome maturation, regulated by kinases including Polo kinase and Aurora kinase, begins with centriole duplication, which occurs in G1 and is triggered by cyclin E/[cdk]{.smallcaps}2 and cyclin D/[cdk]{.smallcaps}2 activity. Elongation of the centriole occurs throughout S phase so that by prophase, the cell has two pairs of centrioles [@b22-co16-2-36]. Aurora kinase regulates spindle pole structure and duplication and separation of the centriole [@b23-co16-2-36],[@b24-co16-2-36]. Survivin, regulated by cyclin B1/[cdc]{.smallcaps}2, regulates the mitotic spindle and cell viability [@b25-co16-2-36]--[@b27-co16-2-36].

3. THE CELL CYCLE AS A TARGET FOR CANCER THERAPEUTICS
=====================================================

The [cdk]{.smallcaps}s are rational targets for cancer therapy. Their expression is often perturbed in malignancy, and their inhibition can induce apoptosis. Most tumour-suppressor genes and oncogenes are part of pathways that control cellular functions, including cell-cycle entry and exit [@b28-co16-2-36],[@b29-co16-2-36]. Checkpoint integrity is often lost as a result of inactivation of [cdki]{.smallcaps}s or of overexpression of cyclins. For example, loss of p16 function is associated with melanoma, lung, breast, and colorectal tumours [@b30-co16-2-36]. Overexpression of cyclin D1 is associated with breast cancer [@b31-co16-2-36],[@b32-co16-2-36]. Thus, targeting [cdk]{.smallcaps}s could restore cell-cycle checkpoints and may slow growth or induce apoptosis [@b33-co16-2-36]. [Figure 1](#f1-co16-2-36){ref-type="fig"} shows the site of action of [cdki]{.smallcaps}s in clinical development.

Inhibitors of [cdk]{.smallcaps} also inhibit transcription. A key enzyme in the transcription machinery, [rna]{.smallcaps} polymerase [ii]{.smallcaps}, is phosphorylated by several [cdk]{.smallcaps}s [@b34-co16-2-36],[@b35-co16-2-36]. The most important regulator is [cdk]{.smallcaps}9/cyclin T. Inhibition of [cdk]{.smallcaps}9/cyclin T by a [cdki]{.smallcaps} such as flavopiridol (discussed in the next subsection) leads to inhibition of [rna]{.smallcaps} polymerase [ii]{.smallcaps} and a decrease in the anti-apoptotic protein Mcl-1 [@b36-co16-2-36]. Apoptosis is induced.

3.1 Flavopiridol
----------------

Flavopiridol is a pan--[cdk]{.smallcaps} inhibitor that blocks [cdk]{.smallcaps}2, -4, and -6 at nanomolar concentrations. *In vitro,* it causes cell-cycle arrest both at the G1/S transition and at the G2/M transition.

Several phase [i]{.smallcaps} and phase [ii]{.smallcaps} studies of flavopiridol have been reported in a variety of solid tumours and hematologic malignancies. A phase [i]{.smallcaps} study in chronic lymphocytic leukemia ([cll]{.smallcaps}) noted some encouraging responses. Flavopiridol was administered weekly for 4 of 6 weeks in 52 patients with refractory [cll]{.smallcaps}. The patients were treated with a 30--40 mg/m^2^ loading dose followed by 30--50 mg/m^2^ over 4 hours. The dose-limiting toxicity ([dlt]{.smallcaps}) was hyperacute tumour lysis syndrome. Partial responses ([pr]{.smallcaps}s) were achieved in 40% of patients, and those responses were durable, with a median progression-free survival of 12 months [@b37-co16-2-36],[@b38-co16-2-36].

Phase [ii]{.smallcaps} studies of flavopiridol as a single agent have been completed in metastatic melanoma [@b39-co16-2-36], endometrial adenocarcinoma [@b40-co16-2-36], and multiple myeloma [@b41-co16-2-36]. No objective evidence of antitumour activity was observed in the 58 patients treated on those studies. Major toxicities were myelosuppression and diarrhea.

Flavopiridol holds more potential as an enhancer of the effects of cytotoxic chemotherapy. A major phase [i]{.smallcaps} study that assessed the combination of flavopiridol and irinotecan enrolled 45 patients. The identified maximum tolerated doses ([mtd]{.smallcaps}s) were irinotecan 100 mg/m^2^ with flavopiridol 60 mg/m^2^ and irinotecan 125 mg/m^2^ with flavopiridol 50 mg/m^2^. Partial responses were observed in 3 patients [@b42-co16-2-36].

Further laboratory work defined the mechanism of activity. By inhibiting [cdk]{.smallcaps}9, flavopiridol inhibited Rad51, a [dna]{.smallcaps} repair protein involved in homologous recombination. This protein sensitizes cells, in a p53-dependent manner, to induction of apoptosis by topoisomerase [i]{.smallcaps} poisons [@b43-co16-2-36].

Other combinations of flavopiridol with chemotherapy have also shown modest activity. A phase [i]{.smallcaps} study of flavopiridol with carboplatin and paclitaxel was performed in 18 patients with previously-untreated non-small-cell lung cancer ([nsclc]{.smallcaps}). Adverse events included nausea, asthenia, and diarrhea. The [mtd]{.smallcaps} of flavopiridol was 70 mg/m^2^ with paclitaxel 175 mg/m^2^ and carboplatin [auc]{.smallcaps} (area under the curve) 5. Of 12 evaluable patients, 8 achieved a [pr]{.smallcaps} [@b44-co16-2-36].

Two phase [i]{.smallcaps} studies of flavopiridol in combination with docetaxel have been reported. In the first, 10 patients were treated with flavopiridol and docetaxel given once every 21 days. The [dlt]{.smallcaps}s were neutropenia and infection. The [mtd]{.smallcaps} was docetaxel 60 mg/m^2^ followed 24 hours later by flavopiridol 50 mg/m^2^ over 24 hours [@b45-co16-2-36]. In the second study, both drugs were administered weekly for 3 in 4 weeks in 27 patients with advanced solid tumours. The [mtd]{.smallcaps} was docetaxel 35 mg/m^2^ followed 4 hours later by flavopiridol 70 mg/m^2^. The best response was an extraordinary complete response in pancreatic cancer. Four [pr]{.smallcaps}s were observed in various tumours [@b46-co16-2-36].

A phase [i]{.smallcaps} study of flavopiridol in combination with either cisplatin or carboplatin in 39 patients has been reported. The [mtd]{.smallcaps} was 60 mg/m^2^ cisplatin and 100 mg/m^2^ flavopiridol over 24 hours. Carboplatin [auc]{.smallcaps} 2 with 100 mg/m^2^ flavopiridol over 24 hours was deemed intolerable because of significant toxicity, including fatigue, nausea, diarrhea, and myelosuppression. The best response was stable disease ([sd]{.smallcaps}) [@b47-co16-2-36].

In a phase [ii]{.smallcaps} study, flavopiridol 50 mg/m^2^ over 1 hour 3 times daily, in combination with cytarabine and mitoxantrone in 49 patients with poor-risk acute myelogenous leukemia ([aml]{.smallcaps}), showed encouraging activity. Tumour lysis occurred in more than half the patients. Complete responses were observed in 75% of patients who were either previously untreated or who had experienced early relapse [@b48-co16-2-36].

In additional to the clinical activity in [cll]{.smallcaps} and [aml]{.smallcaps} already described, preclinical activity of flavopiridol has also been observed in acute lymphoblastic leukemia [@b49-co16-2-36]. A recently developed liposomal formulation of the drug ought to increase the drug's half-life, its [auc]{.smallcaps}, and perhaps its efficacy [@b50-co16-2-36].

3.2 Indisulam
-------------

Indisulam (E7070) is a synthetic sulphonamide that targets the G1 phase of the cell cycle by depleting cyclin E, inducing p53 and p21, and inhibiting [cdc]{.smallcaps}2 phosphorylation [@b51-co16-2-36].

A phase [ii]{.smallcaps} study demonstrated *in vivo* pharmacodynamic ([pd]{.smallcaps}) activity: post-treatment biopsies showed a decrease in Rb phosphorylation. The short duration of the [pd]{.smallcaps} effect led to the conclusion that continuous dosing would likely be required. This finding highlighted the importance of the dose schedule in maintaining a cytostatic effect of drugs that target the cell cycle [@b52-co16-2-36].

Other notable single-agent studies include a phase [ii]{.smallcaps} trial in malignant melanoma. The 28 patients enrolled were treated at a dose of 700 mg/m^2^ every 3 weeks. No objective responses were observed, but minor responses and [sd]{.smallcaps} were seen [@b53-co16-2-36].

In a phase [ii]{.smallcaps} study in second-line therapy for [nsclc]{.smallcaps}, patients were randomized to receive indisulam every 3 weeks either as a single intravenous (IV) dose of 700 mg/m^2^ on day 1 or 130 mg/m^2^ IV on days 1--5. In the 44 patients treated, only minor responses were seen. However, evidence of [pd]{.smallcaps} targeting was observed: flow cytometric analysis of endobronchial and metastatic disease revealed a reduction in the fraction of cycling cells and an increase in apoptosis following indisulam as compared with pretreatment levels. Nevertheless, the drug was considered to have no significant single-agent activity [@b54-co16-2-36].

Combination studies with chemotherapy have also been pursued. A phase [i]{.smallcaps} study of indisulam with carboplatin found the [mtd]{.smallcaps} to be indisulam 500 mg/m^2^ on day 1 with carboplatin [auc]{.smallcaps} 6 given every 4 weeks. Toxicities were thrombocytopenia and neutropenia, and significant myelosuppression prevented treatment on the originally-planned 3-week cycle. The best response was [sd]{.smallcaps} [@b55-co16-2-36].

In a phase [ii]{.smallcaps} study of indisulam in combination with capecitabine, 35 patients were treated. The [mtd]{.smallcaps} for multiple treatment cycles was indisulam 500 mg/ m^2^ on day 1 and capecitabine 1250 mg/m^2^ twice daily on days 1--14 of each 21-day cycle. The best response was 2 [pr]{.smallcaps}s. Toxicities included myelosuppression, stomatitis, and hand--foot syndrome [@b56-co16-2-36].

3.3 AZD5438
-----------

AZD5438 is a novel cyclin-dependent kinase inhibitor with preclinical activity against a range of human tumour xenografts. In a phase [i]{.smallcaps} study in healthy volunteers, the drug was found to have a relatively short half-life of 1--3 hours [@b57-co16-2-36],[@b58-co16-2-36]. Nevertheless, [pd]{.smallcaps} effects were demon-strated; the drug led to statistically significant reductions in the ratio phospho-pRb /total pRb detected at 1.5 hours post-dose, but the effect disappeared at 6 hours post-dose. Thus, given the short half-life and close pharmacokinetic--pharmacodynamic relationship, a sustained-release formulation or multiple daily dosing will be required for further drug development.

A second phase [i]{.smallcaps} study of AZD5438 in patients with advanced solid malignancies has recently been completed. Results have yet to be reported (search for "NCT00088790" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)).

3.4 SNS-032 (BMS-387032)
------------------------

SNS-032 is a potent and selective inhibitor of [cdk]{.smallcaps}2, -7, and -9. A phase [i]{.smallcaps} study of the drug in patients with metastatic solid tumours was recently published. The drug was administered as a weekly 1-hour infusion. Toxicities included fatigue and nausea. No [dlt]{.smallcaps} was observed. Some patients received an oral solution for one of the doses, and pharmacokinetic studies demonstrated that oral administration may be feasible [@b59-co16-2-36].

A second phase [i]{.smallcaps} study of SNS-032 in advanced B-cell lymphoid malignancies is ongoing (search for "NCT00446342" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)).

3.5 Bryostatin-1
----------------

Bryostatin-1 is a macrocyclic lactone that modulates the cell cycle, inducing p21 and inactivating [cdk]{.smallcaps}2 [@b60-co16-2-36]. In a phase [i]{.smallcaps} trial, the drug showed limited single-agent activity in melanoma, ovarian cancer, and non-Hodgkin lymphoma [@b61-co16-2-36]. Bryostatin has been evaluated in combination with chemotherapy in a number of phase [i]{.smallcaps} and phase [ii]{.smallcaps} studies.

A phase [i]{.smallcaps} trial of bryostatin and gemcitabine was conducted in 36 patients with advanced solid tumours. Gemcitabine was administered IV over 30 minutes and was followed by bryostatin IV over 24 hours on days 1, 8, and 15 of a 28-day cycle. Common toxicities were anemia, neutropenia, and thrombocytopenia. The best response was [sd]{.smallcaps} in 8 patients. The recommended phase [ii]{.smallcaps} dose was bryostatin 35 μg/m^2^ and gemcitabine 1000 mg/m^2\ 62^.

Another phase [i]{.smallcaps} study assessed bryostatin and fludarabine in patients with [cll]{.smallcaps} or indolent lymphoma. Fludarabine was given daily for 5 days, and a single dose of bryostatin was given by a 24-hour continuous infusion either before or after the fludarabine. The study concluded that bryostatin can be administered safely and tolerably with full-dose fludarabine (25 mg/m^2^ daily for 5 days). The recommended bryostatin phase [ii]{.smallcaps} dose is 50 μg/m^2^ for both sequences. The combination showed moderate activity, and responses were seen in patients who had previously been treated with fludarabine [@b63-co16-2-36].

A phase [ii]{.smallcaps} study of bryostatin and paclitaxel was performed in patients with gastric or gastroesophageal junction adenocarcinoma. Paclitaxel 80 mg/m^2^ IV over 2 hours was given on day 1, with bryostatin 40 μg/m^2^ IV over 1 hour on day 2 each week for 3 consecutive weeks in 4. There were 35 evaluable patients. The confirmed [pr]{.smallcaps} rate was 29%. Grade 3 cumulative myalgias occurred in 55% of patients [@b64-co16-2-36].

Another phase [ii]{.smallcaps} study assessed bryostatin and paclitaxel in advanced esophageal cancer. The initial dose was paclitaxel 90 mg/m^2^ on day 1 and bryostatin 50 μg/m^2^ on day 2 weekly for 3 consecutive weeks in 4. In 22 evaluable patients, the [pr]{.smallcaps} rate was 27%. Grades 3 and 4 myalgias requiring dose reduction were seen in 50% of patients. The trial was closed early because of toxicity; thus, although antitumour activity was observed, further development will not be pursued [@b65-co16-2-36].

3.6 Seliciclib
--------------

The agent seliciclib \[CYC202, (*R*)-roscovitine\] is a potent oral inhibitor of [cdk]{.smallcaps}2/cyclin E, [cdk]{.smallcaps}1/cyclin B, [cdk]{.smallcaps}7/cyclin H, and [cdk]{.smallcaps}9/cyclin T1 [@b66-co16-2-36],[@b67-co16-2-36]. Seliciclib suppresses genes that inhibit apoptosis and has single-agent *in vitro* activity against a range of tumours [@b68-co16-2-36]--[@b71-co16-2-36]. *In vivo* activity has also been reported for seliciclib against human colon and uterine cancer xenografts [@b72-co16-2-36].

A phase [i]{.smallcaps} study of seliciclib in 22 patients has been completed in Europe [@b73-co16-2-36]. The [mtd]{.smallcaps} was 800 mg twice daily given for 7 in every 21 days. Common side effects were nausea, lethargy, and anorexia. The [dlt]{.smallcaps}s were hypokalemia, rash, and fatigue. No objective responses were reported, but disease stabilization occurred in 8 patients and lasted 18 weeks in a patient with ovarian cancer.

A phase [i]{.smallcaps} study of seliciclib in combination with cisplatin and gemcitabine was performed in the first-line treatment of 27 patients with [nsclc]{.smallcaps}. Seliciclib was administered for 4 in every 7 days. The [dlt]{.smallcaps}s consisted of liver enzyme elevation, nausea, vomiting, and transient hypokalemia. The [mtd]{.smallcaps} was seliciclib 800 mg twice daily with gemcitabine 1000 mg/m^2^ and cisplatin 75 mg/m^2^ Among 14 evaluable patients, 6 [pr]{.smallcaps}s were observed[@b74-co16-2-36]

A phase [ii]{.smallcaps} study of seliciclib as a single agent in patients with previously-treated [nsclc]{.smallcaps} has been closed. No data have yet been reported (search for "NCT00372073" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)).

3.7 PD 0332991
--------------

PD 0332991, a pyrido\[2,3-δ\]pyrimidine-7-one, is a selective inhibitor of [cdk]{.smallcaps}4 and [cdk]{.smallcaps}6[@b75-co16-2-36]. In low micromolar concentrations in *in vitro* and xenograft models, it inhibited a panel of Rb-positive solid tumour cell lines[@b76-co16-2-36],[@b77-co16-2-36]. The drug was also tested *in vitro* against mantle cell lymphoma ([mcl]{.smallcaps})[@b78-co16-2-36]. Translocation-mediated constitutive expression of cyclin D, the partner of [cdk]{.smallcaps}4 and -6, is typical of [mcl]{.smallcaps}. As predicted, cells are sensitive to PD 0332991 at low-nanomolar concentrations.

A phase [i]{.smallcaps} clinical trial with PD 0332991 in patients with Rb-positive advanced solid tumours was performed. The principal and dose-limiting toxicity of PD 0332991 is myelosuppression. The [mtd]{.smallcaps} is 125 mg daily for 21 in every 28 days. On a shorter schedule, slightly higher doses were tolerated[@b79-co16-2-36].

A trial of PD 0332991 in [mcl]{.smallcaps} is ongoing (search for "NCT00420056" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)), as are combination studies with letrozole for breast cancer (search for "NCT00721409") and with bortezomib and dexamethasone for multiple myeloma (search for "NCT00555906").

3.8 SCH 727965
--------------

SCH 727965 is a novel pyrazolo\[1,5-α\]pyrimidine that potently and selectively inhibits [cdk]{.smallcaps}1, [cdk]{.smallcaps}2, [cdk]{.smallcaps}5, and [cdk]{.smallcaps}9. It induces apoptosis in tumour cell lines and growth inhibition or regression in xenograft models. A phase [i]{.smallcaps} study is underway with interim results in 23 patients reported. The drug is administered by 2-hour IV infusion once every 21 days. The most common and dose-limiting toxicity is neutropenia. No objective responses were observed. The drug was safe and well tolerated below the maximum administered dose of 58 mg/m^2\ 80^.

A randomized phase [ii]{.smallcaps} study comparing SCH 727965 with erlotinib in patients with [nsclc]{.smallcaps} and comparing SCH 727965 with capecitabine in patients with advanced breast cancer is underway (search for "NCT00732810" at [www.clinicaltrials.gov/ct2/search](www.clinicaltrials.gov/ct2/search)). A second phase [ii]{.smallcaps} study in acute leukemia is planned (search for "NCT00798213").

4. CONCLUSIONS
==============

Phase [i]{.smallcaps} studies have demonstrated that [cdki]{.smallcaps}s can be safely administered to patients with advanced cancer. Doses with demonstrable [pd]{.smallcaps} effects can be achieved. Single-agent activity in solid tumours has, in general, been disappointing. However, in hematologic malignancies, which may be more sensitive to blockade of cell cycling and induction of apoptosis, encouraging activity has been observed. Examples include flavopiridol as a single agent in [cll]{.smallcaps} or in combination with cytarabine and anthracycline in [aml]{.smallcaps}. The [cdki]{.smallcaps}s may also contribute to overcoming drug resistance, as in the case of flavopiridol combined with fludarabine in fludarabine-refractory [cll]{.smallcaps}.

Activity of these agents in solid tumours has been more modest, and the evidence argues that combination studies with other agents should be pursued, but expectations for response should be modest. Drugs that arrest the cell cycle may, at best, result in stabilization of disease. Nevertheless, the preclinical evidence of induction of apoptosis suggests that cell-cycle inhibitors, if given on the right schedule with the right combination of drugs, may cause tumours to regress.
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